

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 09 JAPIO to be reloaded August 25, 2002
NEWS 20 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 21 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 22 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:35:39 ON 23 AUG 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:35:48 ON 23 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3

DICTIONARY FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10049645.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:36:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 70 TO ITERATE

100.0% PROCESSED 70 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 899 TO 1901

PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full

Examiner Anderson 703-605-1157

10049645 Page 3 08/23/2002

FULL SEARCH INITIATED 14:36:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1424 TO ITERATE


100.0% PROCESSED 1424 ITERATIONS
SEARCH TIME: 00.00.02

121 ANSWERS

L3 121 SEA SSS FUL L1

=> d scan

L3 121 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-
methoxy- (SCI)
MF C19 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
140.66	140.87

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:36:57 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3

L4 11 L3


=> d ibib abs hitstr 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:265369 CAPLUS
 DOCUMENT NUMBER: 134:295620
 TITLE: Preparation and effect of 4-methoxyphenylpropionic acid derivatives useful in insulin resistance improvement
 INVENTOR(S): Shinoda, Masanobu; Emori, Eita; Matsuura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hibara, Taro; Seiki, Hisashi; Clark, Richard; Harada, Hitoshi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025181	A1	20010412	WO 2000-JP6788	20000929
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 2000074499	A5	20010510	AU 2000-74499	20000929
EP 1216980	A1	20020626	EP 2000-962993	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRIORITY APPLN. INFO.:				
			JP 1999-282079	A 19991001
			JP 1999-369442	A 19991227
			JP 2000-38795	A 20000216
			JP 2000-104260	A 20000406
			JP 2000-2000038795A	20000216
			JP 2000-2000104260A	20000406
			WO 2000-JP6788	W 20000929

OTHER SOURCE(S): MARPAT 134:295620
 GI




AB Title compds. (Y:L:X:TZM:CWR1; R1 is hydrogen, hydroxyl, alkyl; L is single bond, double bond, alkylene; M is single bond, alkylene; T is single bond, alkylene; W is carbonyl, amide; X is oxygen, alkenylene; Y is arom. hydrocarbon; Z is arom. hydrocarbon; colon represents single, or double bond; salts, esters, and hydrates are prepd. and are useful in prevention or treatment of diabetes and X-syndrome. Thus, the title

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:152658 CAPLUS
 DOCUMENT NUMBER: 134:193426
 TITLE: Preparation of substituted benzylthiazolidine-2,4-dione derivatives as agonists for peroxisomal proliferator activated receptor (PPAR)
 INVENTOR(S): Miyachi, Hiroyuki; Nomura, Masahiro; Tanase, Takahiro; Murakami, Koji; Tsunoda, Masaki
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014349	A1	20010301	WO 2000-JP5519	20000818
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1213287	A1	20020612	EP 2000-953475	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:				
			JP 1999-235527	A 19990823
			JP 2000-242706	A 20000810
			WO 2000-JP5519	W 20000818


OTHER SOURCE(S): MARPAT 134:193426
 GI




AB The title compds. (I) or pharmaceutically acceptable salts thereof, or hydrates of both (wherein A is CH₂CONH₂, NHCONH₂, CH₂CH₂CO₂, or NHCOCH₂; B is C1-4 lower alkyl, C1-3 lower alkoxy, halogeno, trifluoromethyl, trifluoromethoxy, substituted or unsubstituted Ph, substituted or unsubstituted phenoxyl, or substituted or unsubstituted benzoyl) are prepd. These compds. bind as ligands to human peroxisome proliferator-activated receptor (PPAR) to thereby activate the receptor and exert antihyperglycemic and antihyperlipidemic effects. Thus, 378 mg 5-[(3-amino-4-methoxyphenyl)methyl]thiazolidine-2,4-dione was mixed with 5 mL THF, followed by adding 0.236 mL 4-trifluoromethyl isocyanate with stirring at room temp., and the stirring was continued at room temp. for 6

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

compd. I was prepd. and biol. tested.
 IT 334012-89-4P 334012-92-9P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and effect of methoxyphenylpropionic acid derivs. useful in insulin resistance improvement as PPAR agonists)
 RN 334012-89-4 CAPLUS
 CN Benzenesacetamide, N-(4-chloro-2-fluorophenyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 334012-92-9 CAPLUS
 CN Benzenesacetamide, N-(2,4-dichlorophenyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

h, and left to stand overnight to give 578 5-[(4-methoxy-3-[3-(4-(trifluoromethyl)phenyl)ureido]phenyl)methyl]thiazolidine-2,4-dione (II). II showed the transcription-activating activity for human PPAR.alpha. and PPAR.gamma. in CHO cells with EC50 of 0.55 and 0.43 .mu.M, resp.
 IT 327162-48-1P 327162-51-6P 327162-54-9P 327162-61-8P 327162-62-9P 327162-66-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted benzylthiazolidinedione derivs. as agonists for peroxisomal proliferator activated receptor (PPAR) and antihyperglycemic and antihyperlipidemic agents)
 RN 327162-48-1 CAPLUS
 CN Benzenesacetamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 327162-51-6 CAPLUS
 CN Urea, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-N'-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 327162-54-9 CAPLUS
 CN Benzenesacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 327162-61-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-methoxy-3-[[1-oxo-3-(4-(trifluoromethyl)phenyl)propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 327162-62-9 CAPLUS
CN Benzeneacetamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 327162-66-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-


L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 327162-69-6 CAPLUS
CN [1,1'-Biphenyl]-4-acetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4'-methoxy- (9CI) (CA INDEX NAME)




RN 327162-70-9 CAPLUS
CN [1,1'-Biphenyl]-4-acetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4'-methyl- (9CI) (CA INDEX NAME)




RN 327162-71-0 CAPLUS
CN [1,1'-Biphenyl]-4-acetamide, 4'-chloro-N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 327162-67-4 327162-68-5 327162-69-6
327162-70-9 327162-71-0 327162-72-1
327162-73-2 327162-74-3 327162-75-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted benzylthiazolidinedione derivs. as agonists for peroxisomal proliferator activated receptor (PPAR) and antihyperglycemic and antihyperlipidemic agents)

RN 327162-67-4 CAPLUS
CN Benzeneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 327162-68-5 CAPLUS
CN Benzeneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-methoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 327162-72-1 CAPLUS
CN Benzeneacetamide, 4-(4-chlorophenoxy)-N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 327162-73-2 CAPLUS
CN Benzeneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-[(4-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 327162-74-3 CAPLUS
CN Benzeneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 327162-75-4 CAPLUS
 CN Benzeneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxyphenyl]-4-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:5389 CAPLUS
 DOCUMENT NUMBER: 128:114893
 TITLE: Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships

AUTHOR(S): Arakawa, Kenji; Inamasu, Masanori; Matsumoto, Mamoru; Okumura, Kunito; Yasuda, Kosuke; Akatsuka, Hidenori; Kawanami, Saburo; Watanabe, Akishige; Homma, Koichi; Saiga, Yutaka; Ozeki, Masakatsu; Iijima, Ikuro

CORPORATE SOURCE: Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(12), 1984-1993

PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Pharmaceutical Society of Japan
 LANGUAGE: Journal


AB Benzoxazole 2,4-thiazolidinediones were synthesized and evaluated for hypoglycemic activity in genetically obese and diabetic yellow KK mice. 2-Arylmethyl- and 2-(heteroarylmethyl)benzoxazole derivs. showed far more potent activity than known 2,4-thiazolidinedione derivs. such as ciglitazone, troglitazone and pioglitazone. A facile synthesis of benzoxazole 2,4-thiazolidinediones was also established using aminophenol 2,4-thiazolidinedione as a key intermediate. Details of synthesis and structure-activity relations for this series are described.

IT 201802-07-5 201802-09-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents)

RN 201802-07-5 CAPLUS
 CN [1,1'-Biphenyl]-4-acetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A

Ph

RN 201802-09-7 CAPLUS
 CN Benzeneacetamide, 4-(dimethylamino)-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 2-A


NMe2

IT 130769-07-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents)

RN 130769-07-2 CAPLUS
 CN Benzeneacetamide, 4-chloro-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A


I
Cl

- IT 201802-02-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents)
 RN 201802-02-0 CAPLUS
 CN 2-Naphthaleneacetamide, N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

- 195603-81-7P 195603-82-8P 195603-83-9P
 195603-84-0P 195603-85-1P 195603-86-2P
 195603-87-3P 195603-88-4P 195603-89-5P
 195603-90-6P 195603-91-7P 195603-92-0P
 195603-93-1P 195603-94-2P 195603-95-3P
 195603-96-4P 195603-97-5P 195603-98-6P
 195603-99-7P 195604-00-3P 195604-01-4P
 195604-09-2P 195604-10-3P 195604-11-6P
 195604-12-7P 195604-13-8P 195604-14-9P
 195604-16-1P 195604-17-2P 195604-18-3P
 195604-19-4P 195604-20-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of thiazolidinedione derivs. with activity for lowering blood sugar and lipid for treatment of diabetes)
 RN 195603-78-2 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 195603-79-3 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 1997:618083 CAPLUS
 DOCUMENT NUMBER: 127:248106
 TITLE: Preparation of thiazolidine-2,4-dione derivatives for the treatment of diabetes
 INVENTOR(S): Taira, Seizo; Sugimoto, Atsushi
 PATENT ASSIGNEE(S): Torii Pharmaceutical Co., Ltd., Japan; Taira, Seizo; Sugimoto, Atsushi
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732863	A1	19970912	WO 1997-JP639	19970303
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG AU 9722313 A1 19970922 AU 1997-22313 19970303 PRIORITY APPLN. INFO.: JP 1996-51532 19960308 WO 1997-JP639 19970303 OTHER SOURCE(S): MARPAT 127:248106 GI				




- AB Novel thiazolidine-2,4-dione derivs. represented by general formula [I]: R1 = cycloalkyl, substituted or unsubstituted Ph, naphthyl, or a mono- or bicyclic heterocyclyl group contg. one or more atoms selected from among nitrogen, oxygen and sulfur; R2, R3 = hydrogen, lower alkyl, cycloalkyl, alkoxy, halogeno, hydroxy, (optionally protected) amino, Ph or (CH2)n (wherein n = 2 to 6); A = an amide linkage, in particular NHCO or CONH or salts thereof, which possess excellent activity for lowering blood sugar and lipid and alleviate insulin resistance of peripheral tissues, are prepd. Diabetes remedies contg. I as the active ingredients are claimed. Thus, 5-(4-aminobenzyl)thiazolidine-2,4-dione was condensed with (R)-2-phenylpropionic acid using 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in DMF to give I [R1R2R3C-A = (R)-PhMeCHCONH], which at 100 mg/kg p.o. in vivo lowered 54% blood sugar in mice.
 IT 195603-78-2P 195603-79-3P 195603-80-6P

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




- RN 195603-80-6 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)



- RN 195603-81-7 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A



RN 195603-82-8 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 195603-83-9 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195603-84-0 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 195603-85-1 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 195603-86-2 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195603-87-3 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-methyl-
 (9CI) (CA INDEX NAME)




RN 195603-88-4 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-4-methyl-
 (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195603-90-8 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-fluoro-
 (9CI) (CA INDEX NAME)



RN 195603-91-9 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-4-fluoro-
 (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A



RN 195603-89-5 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2-fluoro-
 (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 195603-92-0 CAPLUS
 CN Benzeneacetamide, 2-chloro-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-
 (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195603-93-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-
(9CI) (CA INDEX NAME)




RN 195603-94-2 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-
(9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195603-96-4 CAPLUS
CN Benzeneacetamide, N-[(4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-
hydroxy- (9CI) (CA INDEX NAME)



RN 195603-97-5 CAPLUS
CN Benzeneacetamide, N-[(4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-4-
hydroxy- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A

Cl

RN 195603-95-3 CAPLUS
CN Benzeneacetamide, N-[(4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-2-
hydroxy- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A

OH

RN 195603-98-6 CAPLUS
CN [1,1'-Biphenyl]-4-acetamide, N-[(4-[(2,4-dioxo-5-
thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A

Ph

RN 195603-99-7 CAPLUS
 CN Benzeneacetamide, 4-(dimethylamino)-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A


NMe2

RN 195604-00-3 CAPLUS
 CN 1-Naphthaleneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195604-01-4 CAPLUS
 CN 2-Naphthaleneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 195604-09-2 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-methyl-, [5(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 195604-10-5 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-methyl-, [5(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 195604-11-6 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-ethyl-, (9CI) (CA INDEX NAME)




RN 195604-12-7 CAPLUS
 CN Benzeneacetamide, .alpha.-cyclopentyl-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 195604-13-8 CAPLUS
 CN Benzeneacetamide, .alpha.-cyclohexyl-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195604-14-9 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 195604-16-1 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195604-17-2 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.,.alpha.-diethyl- (9CI) (CA INDEX NAME)




RN 195604-18-3 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.,.alpha.-diphenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 195604-19-4 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-methyl-2-nitro- (9CI) (CA INDEX NAME)



RN 195604-20-7 CAPLUS
 CN Benzeneacetamide, N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-.alpha.-methyl-4-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



PAGE 1-A


NO₂

PAGE 2-A

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:245079 CAPLUS
 DOCUMENT NUMBER: 120:245079
 TITLE: Preparation of thiazolidine-2,4-dione derivatives as
 antidiabetics
 INVENTOR(S): Myaoka, Shozo; Sato, Hiroko; Takahashi, Keimei;
 Ushijima, Hideto
 PATENT ASSIGNEE(S): Terumo Corp, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05310718	A2	19931122	JP 1992-110460	19920428


OTHER SOURCE(S): MARPAT 120:245079
 GI



AB The title derivs. I (R1, R2 = H, OH, lower alkoxy, alkoxy-methoxy) are prepd. A mixt. of 25.0 g 5-(3-acetylbenzyl)thiazolidine-2,4-dione (prepd. from *m*-aminoacetophenone in 2 steps), 19.7 g 3-methoxy-4-methoxymethoxybenzaldehyde, and aq. KOH in MeOH was treated at room temp. for 2.5 h to give 23.1 g 5-[3-(3-methoxy-4-methoxymethoxyphenyl)-2-propenyl]benzylthiazolidine-2,4-dione, which (6.20 g) was treated with *tert*-Bu bromacetate in the presence of K2CO3 in DMF at room temp. for 1.5 h to give 3-*tert*-butoxycarbonylmethyl-5-[3-(3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]benzylthiazolidine-2,4-dione (II). II (4.30 g) was stirred at room temp. in HCO2H for 2.5 h to give 2.70 g I (R1 = OMe, R2 = OH) (III). III inhibited aldose reductase with IC50 of 1.4 times 10⁻⁷.


IT 154066-94-1P 154066-95-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and deprotection of)
 RN 154066-94-1 CAPLUS
 CN 3-Thiazolidineacetic acid, 5-[[3-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-2,4-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154066-95-2 CAPLUS
 CN 3-Thiazolidineacetic acid, 5-[[4-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-2,4-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



IT 145704-71-8P 145704-74-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and protection of)
 RN 145704-71-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 145704-74-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 154066-96-3P 154066-97-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antidiabetic)
 RN 154066-96-3 CAPLUS
 CN 3-Thiazolidineacetic acid, 5-[[3-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 154066-97-4 CAPLUS
 CN 3-Thiazolidineacetic acid, 5-[[4-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:80926 CAPLUS
 DOCUMENT NUMBER: 118:80926
 TITLE: Thiazolidine-2,4-dione compounds, method for their


production, and medicines containing them for treatment of diabetic complications
 INVENTOR(S): Miyaoka, Shozo; Takahashi, Hiroaki; Ushijima, Hideto; Sato, Hiroko

PATENT ASSIGNEE(S): Terumo Corp., Japan
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 489663	A1	19920610	EP 1991-403312	19911206
R1 BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 04210683	A2	19920731	JP 1990-413602	19901206
US 5225426	A	19930706	US 1991-802308	19911204
PRIORITY APPLN. INFO.:			JP 1990-413602	19901206
OTHER SOURCE(S):		MARPAT 118:80926		
GI				




AB Title compds. I (R1 = H, Me) are prepd. as antidiabetic drugs with a combined action, both inhibiting aldose reductase and depressing blood sugar. For example, condensation of 5-(4-acetylbenzyl)thiazolidine-2,4-dione (prepd. in 2 steps) with 3,4-(MeO)(MeOCH2O)C6H3CHO in methanolic KOH, and deprotection of the product by HCl in aq. THF-MeOH, gave I (R1 = Me; CH2 group in 4-position (II)). At 100 mg/kg/day orally for 4 days in diabetic rats, II gave 93.8% inhibition of sorbitol accumulation and 60.5% drop in blood sugar, whereas a comparative thiazoleacetic acid deriv. gave 90.3% inhibition of sorbitol but only 7.2% blood sugar drop. Prepn. and biol. data for 3 I are described; these and 3 addnl. I are claimed.

IT 145704-70-7P 145704-71-8P 145704-74-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)

RN 145704-70-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[3,4-bis(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A



RN 145704-71-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 145704-74-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 145704-63-8P 145704-64-9P 145704-65-0P
 145704-66-1P 145704-67-2P 145704-68-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (prepn. of, as antidiabetic)
 RN 145704-63-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 145704-64-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 145704-66-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 145704-67-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[2-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 145704-68-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[2-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A





RN 145704-65-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:255519 CAPLUS
 DOCUMENT NUMBER: 116:255519
 TITLE: Novel thiazolidine-2,4-diones as potent euglycemic agents.
 AUTHOR(S): Hulin, Bernard; Clark, David A.; Goldstein, Steven W.; McDermott, Ruth E.; Dambek, Paul J.; Kappeler, Werner H.; Lamphere, Charles H.; Lewis, Diana M.; Rizzi, James P.
 CORPORATE SOURCE: Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: J. Med. Chem. (1992), 35(10), 1853-64
 CODEN: JMCHAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A new series of thiazolidine-2,4-diones I [R = H, Z = O, X = (CH₂)_n, (n = 1, 2, 3), OCH₂, CH₂CH₂; R = 4-PhCH₂O, 4-MeO, 2-MeO, Z = O, X = CH₂CH₂; R = H, Z = H₂ or H₂O, X = CH₂CH₂; R = 4-PhCH₂O, 2-MeO, 2-Cl, 2-CH₃, 2-PhCH₂, 3-Cl, 4-Br, 4-EtO₂C, 4-Ph, 2-HO, 2-Me, 4-MeOCH₂, 4-MeO, 4-Me₂N, Z = O, X = CH₂CH₂] was obtained by replacing the ether function of enlitazone with various functional groups, i.e., a ketone, alc., or olefin moiety. These compds. lower blood glucose levels in the genetically obese and insulin-resistant ob/ob mouse. Appending an oxazole-based group at the terminus of the chain provided highly potent compds., e.g. II [R₁ = Ph, 4-MeC₆H₄, R₂ = Me, H; R₁ = 4-MeOC₆H₄, 4-CH₃C₆H₄, 4-HOC₆H₄, 3,5,4-Me₂(MeO)₂C₆H₂, 3,5,4-Me₂(HO)₂C₆H₂, 2-furyl, 2-(5-methylfuryl), 2-HSC₆H₄, 2-naphthyl, R₂ = Me].

IT 141199-92-0P 141199-93-1P 141199-94-2P
 141199-96-4P 141199-99-7P 141200-00-2P
 141200-01-3P 141200-02-4P 141200-04-6P
 141200-05-7P 141200-06-8P 141200-08-0P
 141200-09-1P 141200-10-4P 141200-12-6P
 141200-13-7P 141200-15-9P 141200-16-0P
 141221-04-7P 141221-05-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and euglycemic activity of)
 RN 141199-92-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A



RN 141199-93-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3-{[1,1'-biphenyl]-4-yl}-1-oxopropyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 141199-94-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3-{[2-methoxyphenyl]-1-oxopropyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 141199-96-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3-{[4-methoxyphenyl]-1-oxopropyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A




RN 141199-99-7 CAPLUS
RN 141200-00-2 CAPLUS
RN 141200-01-3 CAPLUS
RN 141200-02-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(1-oxo-3-{[2-(trifluoromethyl)phenyl]-2-propenyl)phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 141200-04-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(1-oxo-3-{[2-(phenylmethyl)phenyl]-2-propenyl)phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141200-05-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(1-oxo-3-{[3-chlorophenyl]-1-oxo-2-propenyl)phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 141200-06-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(1-oxo-3-{[4-bromophenyl]-1-oxo-2-propenyl)phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 141200-08-0 CAPLUS
 RN 141200-09-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(2-methylphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 141200-10-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[4-(methoxymethyl)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141200-12-6 CAPLUS
 RN 141200-13-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 141200-07-9 CAPLUS
 RN 141200-11-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[4-(methoxymethyl)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Na

RN 141200-14-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Na

RN 141200-17-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[4-(1-hydroxy-3-phenylpropyl)phenyl]methyl]-, monosodium salt, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na


RN 141200-18-2 CAPLUS

Examiner Anderson 703-605-1157

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 141200-15-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(1-hydroxy-3-phenylpropyl)phenyl]methyl]-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 141200-16-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(1-hydroxy-3-phenylpropyl)phenyl]methyl]-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 141221-04-7 CAPLUS
 CN Benzoic acid, 4-[3-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]-3-oxo-1-propenyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 141221-05-8 CAPLUS
 IT 141199-95-3P 141199-97-5P 141200-03-5P
 141200-07-9P 141200-11-5P 141200-14-8P
 141200-17-1P 141200-18-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 141199-95-3 CAPLUS
 RN 141199-97-5 CAPLUS
 RN 141200-03-5 CAPLUS

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(1-hydroxy-3-phenylpropyl)phenyl]methyl]-, monosodium salt, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Na

IT 141199-98-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn., conjugate redn. or hydrogenolysis, and euglycemic activity of)
 RN 141199-98-6 CAPLUS
 IT 141199-98-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn., redn., and euglycemic activity of)
 RN 141199-98-4 CAPLUS

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:55794 CAPLUS
 DOCUMENT NUMBER: 114:55794
 TITLE: Hypolipemics containing (thiazolidinylmethyl)benzoxazoles or (thiazolidinylidenemethyl)benzoxazoles
 INVENTOR(S): Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunito; Mori, Tetsuji; Inamasu, Masanori
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02167224	A2	19900627	JP 1989-216742	19890822
JP 05039927	B4	19930616		
WO 9119496	A1	19911226	WO 1990-JP791	19900618
W: CA, KR, US				
RU: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
JP 05194221	A2	19930803	JP 1992-257107	19920811
JP 2518497	B2	19960724		

PRIORITY APPLN. INFO.: JP 1988-229088 19880913
 OTHER SOURCE(S): MARPAT 114:55794
 GI




AB Hypolipemics contain title compds. I [R = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl; Alk = bond, lower alkenylene, lower alkynylene, (un)substituted lower alkylene; the dotted line may be a double bond] or their pharmacol. acceptable salts as active ingredients. Treatment of THF-DMF soln. contg. 3.10 g 5-(3-amino-4-hydroxybenzyl)-2,4-dioxothiazolidine (prepn. given) and N,N-dimethylaniline with a THF soln. of 2.38 g 2-phenyl-4-thiazoleacetyl chloride at room temp. for 20 min gave 3.35 g N-[(2,4-dioxothiazolidin-5-yl)methyl-2-hydroxyphenyl]-2-phenylthiazol-4-acetamide, which was treated with trimethylsilyl polyphosphate at 100.degree. for 30 min to afford 61% 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzoxazole (II). Rats were fed a high-cholesterol diet contg. 10 mg% (sic) II for 3 days, resulting in decrease in serum cholesterol level by 30, increase in high-d. lipoprotein cholesterol level 82, and decrease in triglyceride 46%.

IT 110383-54-3P

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:604 CAPLUS
 DOCUMENT NUMBER: 114:604
 TITLE: (Thiazolidinylmethyl)benzoxazoles or (thiazolidinylidenemethyl)benzoxazoles as hypoglycemics
 INVENTOR(S): Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunito; Inamasu, Masanori
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02167225	A2	19900627	JP 1989-232385	19890907
JP 05039928	B4	19930616		
JP 05194222	A2	19930803	JP 1992-257106	19920811


PRIORITY APPLN. INFO.: JP 1988-233199 19880916
 OTHER SOURCE(S): MARPAT 114:604
 GI



AB Hypoglycemics contain title compds. I [R = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl; Alk = bond, lower alkenylene, lower alkynylene, (un)substituted lower alkylene; the dot line may be double bond] or their pharmacol. acceptable salts as active ingredients. Treatment of THF-DMF soln. contg. 3.10 g 5-(3-amino-4-hydroxybenzyl)-2,4-dioxothiazolidine (prepn. given) and N,N-dimethylaniline with THF soln. of 2.38 g 2-phenyl-4-thiazoleacetyl chloride at room temp. for 20 min gave 3.35 g N-[(2,4-dioxothiazolidin-5-yl)methyl-2-hydroxyphenyl]-2-phenylthiazol-4-acetamide, which was then treated with trimethylsilyl polyphosphate at 100.degree. for 30 min to afford 61% 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzoxazole (II). Hypoglycemic effects of II (administered in diet) were demonstrated in rats.


IT 130769-07-2P
 RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of)
 RN 130769-07-2 CAPLUS
 CN Benzeneacetamide, 4-chloro-N-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and reaction of)
 RN 118383-54-3 CAPLUS
 CN Benzeneacetamide, 4-chloro-N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:406325 CAPLUS
 DOCUMENT NUMBER: 113:6325
 TITLE: Preparation of thiazolidinediones as hypoglycemic agents
 INVENTOR(S): Clark, David Alan; Goldstein, Steven Wayne; Holland, Gerald Fagan; Hulin, Bernard; Rizzi, James Patrick
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 46 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 332331	A2	19890913	EP 1989-302012	19890228
EP 332331	A3	19891129		
EP 332331	B1	19940209		
WO 8908650	A1	19890921	WO 1988-US744	19880308
W: FI, HU, NO, US				
HU 56357	A2	19910828	HU 1988-2857	19880308
AT 101394	E	19940215	AT 1989-302012	19890228
ZA 8901682	A	19901031	ZA 1989-1682	19890306
CA 1328872	A1	19940426	CA 1989-592854	19890306
DK 8901082	A	19890911	DK 1989-1082	19890307
AU 8931075	A1	19890914	AU 1989-31075	19890307
AU 593758	B2	19900215		
JP 01272573	A2	19891031	JP 1989-54841	19890307
JP 2569167	B2	19970108		
US 5061717	A	19911029	US 1990-566436	19900814
NO 9003862	A	19900905	NO 1990-3862	19900905
US 5120754	A	19920609	US 1991-679898	19910403
US 5223522	A	19930629	US 1992-857039	19920324
PRIORITY APPLN. INFO.:			WO 1988-US744	19880308
			EP 1989-302012	19890228
			US 1990-566436	19900814
			US 1991-679898	19910403

OTHER SOURCE(S): CASREACT 113:6325; MARPAT 113:6325
 GI




AB Title compds. I (A, B = CH, N; X = S, SO, SO2, CH2, CHOH, CO; X1, X2 = H,

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




● Na

RN 125679-04-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(2-methylphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.



● Na

RN 125679-05-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(4-bromophenyl)-1-oxo-2-propenyl]phenyl]methyl]-, potassium salt, (E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.




● X

RN 125679-06-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(4-nitrophenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 Me, F3C, Ph, PhCH2, HO, MeO, PhO, PhCH2O, Br, Cl, F; Y = R1CH, R2N; Z = R3CH, CH2CH2, CH:CH, etc.; R, R1, R2, R3 = H, Me; n = 0, 1) and a pharmaceutically acceptable salt, useful for lowering blood glucose or blood cholesterol, are prepd. 2,4-Thiazolidinedione in THF was cooled to -78.degree. and BuLi was added followed by 4-(BrCH2)C6H4SO2NMeCH2Ph in THF to give I (A = B = CH, X = SO2, X1 = X2 = H, Yn = MeN, Z = R = CH2). I have demonstrated their hypoglycemic and hypocholesterolemic activity.
 IT 125679-02-9P 125679-03-0P 125679-04-1P
 125679-05-2P 125679-06-3P 125679-07-4P
 125679-08-5P 125679-09-6P 125679-10-9P
 125679-11-0P 125679-12-1P 125679-13-2P
 125679-14-3P 125679-15-4P 125679-16-5P
 125679-17-6P 125679-18-7P 125679-19-8P
 125679-20-9P 125679-21-6P 125679-22-7P
 125679-23-8P 125679-24-9P 125679-25-0P
 125758-73-8P 125758-74-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as hypocholesteremic and hypoglycemic)
 RN 125679-02-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[1-oxo-3-[2-(trifluoromethyl)phenyl]-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● Na

RN 125679-03-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[1-oxo-3-[2-(phenylmethyl)phenyl]-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




● Na

RN 125679-07-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(3-chlorophenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.



● Na


RN 125679-08-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(3-nitrophenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.



● Na

RN 125679-09-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(2-hydroxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, monosodium salt, (E)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
Double bond geometry as shown.



● Na

RN 125679-10-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-[(methylsulfonyl)oxy]phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Na

RN 125679-11-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Na

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



Ph

● Na


RN 125679-15-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 2-A

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 125679-12-1 CAPLUS
CN Acetamide, N-[4-[[3-[[4-[[2,4-dioxo-5-thiazolidinyl]methyl]phenyl]-3-oxo-1-propenyl]phenyl]-, monosodium salt, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na


RN 125679-13-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-methoxyphenyl)-1-oxopropyl]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 125679-14-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-[[1,1'-biphenyl]-4-yl]-1-oxopropyl]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



● Na

RN 125699-10-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-[[4-(methoxymethoxy)phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, sodium salt, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Na

RN 125699-11-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1-oxo-3-phenylpropyl)phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




● Na

RN 125699-12-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(4-methoxyphenyl)-1-oxopropyl]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 125734-16-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-chlorophenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 125734-17-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-methoxymethoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 125734-18-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(4-phenylmethoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 125734-19-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-hydroxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


Examiner Anderson 703-605-1157

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued) PAGE 2-A



● Na


RN 125699-13-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1-hydroxy-3-phenylpropyl)phenyl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 125734-14-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1-oxo-3-phenyl-2-propenyl)phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 125734-15-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 125734-20-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 125734-21-6 CAPLUS
CN Acetamide, N-[[4-[[3-(4-(2,4-dioxo-5-thiazolidinyl)methyl]phenyl)-3-oxo-1-propenyl]phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 125734-22-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1-oxo-3-phenylpropyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 125734-23-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[1-oxo-3-[4-(phenylmethyl)phenyl]propyl]phenylmethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 125734-24-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(3-methoxyphenyl)-1-oxopropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 125758-74-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[2-[(methylsulfonyl)oxy]phenyl]-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 125734-25-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[1-hydroxy-3-phenylpropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 125758-73-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-[1,1'-biphenyl]-1-oxo-2-propenyl]phenyl]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:57657 CAPLUS
 DOCUMENT NUMBER: 110:57657
 TITLE: Preparation of 5-(benzoxazolymethyl[or methylene])-2,4-thiazolidinediones as antidiabetics
 Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunihito
 Inamasu, Masanori
 PATENT ASSIGNEE(S): Tanabe Seliyaku Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283035	A1	19880921	EP 1988-104361	19880318
EP 283035	B1	19911106		
Ri AT, BE, CH, DE, ES, GB, GR, IT, LI, LU, NL, SE				
FI 8801103	A	19880919	FI 1988-1103	19880309
FI 91869	B	19940513		
FI 91869	C	19940825		
JP 01056675	A2	19900303	JP 1988-58068	19880310
JP 05005832	B4	19930125		
US 4897393	A	19900130	US 1988-167391	19880314
AU 8813177	A1	19880922	AU 1988-13177	19880316
AU 600805	B2	19900823		
CA 1304371	A1	19920630	CA 1988-561556	19880316
DK 8801474	A	19880919	DK 1988-1474	19880317
CN 88101542	A	19881005	CN 1988-101542	19880317
CN 1026322	B	19941026		
HU 50339	A2	19900129	HU 1988-1317	19880317
HU 204525	B	19920128		
IL 102894	A1	19930221	IL 1988-102894	19880317
IL 85767	A1	19930818	IL 1988-85767	19880317
FR 2612516	A1	19880923	FR 1988-3570	19880318
FR 2612516	B1	19921113		
AT 69225	E	19911115	AT 1988-104361	19880318
ES 2037752	T3	19930701	ES 1988-104361	19880318
US 4948900	A	19900814	US 1989-435807	19891113
AU 9055783	A1	19901011	AU 1990-55783	19900521
AU 618483	B2	19911219		
CA 1326489	A2	19940125	CA 1991-616209	19911024
PRIORITY APPLN. INFO.:			JP 1987-63359	19870318
			JP 1987-67073	19870320
			US 1988-167391	19880314
			CA 1988-561556	19880316
			IL 1988-85767	19880317
			EP 1988-104361	19880318

OTHER SOURCE(S): CASREACT 110:57657; MARPAT 110:57657
 GI For diagram(s), see printed CA Issue.
 AB The title compds. [1; R - (un)substituted cycloalkyl, Ph, naphthyl, heterocyclyl] 2 - bond, alkenylene, alkynylene, (un)substituted alkylene; dotted line is optional double bond] and their pharmaceutically acceptable salts were prepd. as hypoglycemics, useful in treating diabetes. 4-HZNC6H4OH was converted in 3 steps to 5-(p-hydroxybenzyl)-2,4-thiazolidinedione which was nitrated and reduced to give 5-(3-amino-4-hydroxybenzyl)-2,4-thiazolidinedione. The latter was N-acylated with 2-phenyl-4-thiazoleacetyl chloride and the resulting

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS (Continued)
 anilide was cyclized by heating at 100.degree. in ClCH₂CH₂Cl with P2O₅ and
 (Me₃Si)₂O to give (thiazolylmethyl)benzoxazole II. Genetically obese and
 diabetic mice given feed contg. 0.5 mg% II for 5 days had their blood
 glucose level reduced 63%.
 IT 118383-54-3P 118383-57-6P
 RL: RCT (Reactant); SPW (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, in prepn. of hypoglycemics)
 RN 118383-54-3 CAPLUS
 CN Benzeneacetamide, 4-chloro-N-[5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-
 hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 118383-57-6 CAPLUS
 CN Benzeneacetamide, 4-[(dimethylamino)-N-[5-[(2,4-dioxo-5-
 thiazolidinyl)methyl]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

51.45

192.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

SESSION

CA SUBSCRIBER PRICE

-6.82

-6.82

STN INTERNATIONAL LOGOFF AT 14:41:34 ON 23 AUG 2002